1-9 of 9
Timothy Illidge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

John Radford, Joanna Williams, Darren Edwards, Ruth Pettengell, Peter Johnson, Peter Hoskin, Timothy Illidge, Nicholas Counsell
Journal: Blood
Blood (2024) 144 (Supplement 1): 457.
https://doi.org/10.1182/blood-2024-200662
Published: 2024
Journal Articles

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Kim M Linton, MBChB, PhD, Joanna M Oladipo, PhD, Nicholas Counsell, MSc, Janet Taylor, PhD, Cathy Burton, MBBChir, MA, MD FRCPath, Rachel Oakley, PhD, Joanna Williams, PhD, Sally F Barrington, Prof, MD PhD, Richard Byers, BSc, MSc, MBChB, PhD FRCPath, Timothy Illidge, MDPhD, John A. Radford, MD FMedSci
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136318
Published: 2020
Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Kerry J Savage, BSc, MD MSc, Steven M. Horwitz, MD, Ranjana H Advani, MD, Jacob H. Christensen, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, Franck Morschhauser, MD, Onder Alpdogan, MD, Cheolwon Suh, Kensei Tobinai, MD PhD, Andrei R Shustov, MD, Marek Trneny, MD prof, Sam Yuen, MBBS,FRCPA,FRACP, Pier Luigi Zinzani, MD PhD, Lorenz Truemper, MD, Timothy Illidge, MD PhD, Owen O'Connor, MD PhD, Barbara Pro, MD, Meredith Little, MPH, Veronica Bunn, Keenan Fenton, Thomas Manley, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 464.
https://doi.org/10.1182/blood-2019-122781
Published: 2019
Journal Articles

Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Martine Bagot, MD PhD, Timothy Illidge, MD PhD, Nicola Pimpinelli, MD, Mehul Dalal, PhD, Athanasios Zomas, Chalid Assaf, MD, Nathalie Waser, PhD, Zhouqin He, MSc, Tina Li, MPH, Robert Sambrook, MSc, Fabrizio Trinchese, Meredith Little, Nawal Bent-Ennakhil, Pablo L. Ortiz-Romero, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5879.
https://doi.org/10.1182/blood-2019-126246
Published: 2019
Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1547.
https://doi.org/10.1182/blood-2019-124351
Published: 2019
Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

John Radford, Sally Barrington, Nicholas Counsell, Ruth Pettengell, Peter Johnson, Jennie Wimperis, Stewart Coltart, Dominic Culligan, Andrew Lister, Eric Bessell, Anton Kruger, Bilyana Popova, Barry Hancock, Peter Hoskin, Timothy Illidge, Michael O'Doherty
Journal: Blood
Blood (2012) 120 (21): 547.
https://doi.org/10.1182/blood.V120.21.547.547
Published: 2012
Journal Articles

Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy.

Sally F Barrington, Michael J O’Doherty, Jane MacKewn, Paul Schleyer, Wendi Qian, Philippa Patrick, Timothy Illidge, Ruth Pettengell, Peter Hoskin, Barry Hancock, John Radford
Journal: Blood
Blood (2008) 112 (11): 1449.
https://doi.org/10.1182/blood.V112.11.1449.1449
Published: 2008
Journal Articles

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

John Radford, Michael O’Doherty, Sally Barrington, Wendi Qian, Philippa Patrick, Stewart Coltart, Dominic Culligan, Jennie Wimperis, Eric Bessell, David Linch, Peter Johnson, David Cunningham, T. Andrew Lister, Peter Hoskin, Ruth Pettengell, Barry Hancock, Timothy Illidge
Journal: Blood
Blood (2008) 112 (11): 369.
https://doi.org/10.1182/blood.V112.11.369.369
Published: 2008
Journal Articles

Clinical quantitation of immune signature in follicular lymphoma by RT-PCR–based gene expression profiling

Richard J. Byers, Ebrahim Sakhinia, Preethi Joseph, Caroline Glennie, Judith A. Hoyland, Lia P. Menasce, John A. Radford, Timothy Illidge
Journal: Blood
Blood (2008) 111 (9): 4764–4770.
https://doi.org/10.1182/blood-2007-10-115915
Published: 2008
Includes: Supplemental data